Neumora Therapeutics’ stock craters after trial of major depressive disorder fails to meet main goals 2 de janeiro de 2025 by in News News is a setback for the clinical-stage biotech and a drug that proved successful in earlier trials Compartilhe isso:Clique para compartilhar no Twitter(abre em nova janela)Clique para compartilhar no Facebook(abre em nova janela) Relacionado 2 de janeiro de 2025